The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells

ASIAIR > College of Medical and Health Science > Department of Biotechnology > Journal Article > Item 310904400/4637

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/4637

Title:	The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
Authors:	Nahta, R.;Mien-Chie Hung;Esteva F. J.
Date:	2004
Issue Date:	2009-11-27 05:57:10 (UTC+0)
Publisher:	Asia University
Abstract:	Trastuzumab (herceptin) and pertuzumab (Omnitarg, 2C4) are recombinant humanized monoclonal antibodies that target different extracellular regions of the HER-2 tyrosine kinase receptor. We explored combination effects of these agents in the HER-2-overexpressing BT474 breast cancer cell line. Trastuzumab and 2C4 synergistically inhibited the survival of BT474 cells, in part, because of increased apoptosis. Trastuzumab increased 2C4-mediated disruption of HER-2 dimerization with the epidermal growth factor receptor and HER-3. Combination drug treatment reduced levels of total and phosphorylated HER-2 protein and blocked receptor signaling through Akt but did not affect mitogen-activated protein kinase. These results suggest that combining HER-2-targeting agents may be a more effective therapeutic strategy in breast cancer rather than treating with a single HER-2 monoclonal antibody.
Relation:	CANCER RESEARCH 64(7):2343-2346
Appears in Collections:	[Department of Biotechnology] Journal Article

Files in This Item:

File	Description	Size	Format
		0Kb	Unknown	613	View/Open
310904400-4637.doc		32Kb	Microsoft Word	430	View/Open